Sa PEDL, Mota ML, Sa PAD, Otavio ML, Budag MJ, et al. (2018) Prognostic Factors in Breast Cancer: From Staging to the Immunohistochemical Profile of Patients with Breast Cancer in a Reference Hospital of Ceara - Brazil. Int Arch Med Microbiol 1:005.


© 2018 Sa PEDL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

RESEARCH ARTICLE | OPEN ACCESS DOI: 10.23937/iamm-2017/1710005

Prognostic Factors in Breast Cancer: From Staging to the Immunohistochemical Profile of Patients with Breast Cancer in a Reference Hospital of Ceara - Brazil

Pires Eduardo De Lima Sa1,2*, Morais Livia Mota3, Pires Amanda De lima Sa4, Matsuda Luis Otavio4, Matsuda Josie Budag4 and Alves Angelo Roncalli Melo1,2

1Department of Medicine, Universidade Estadual do Ceara, Brazil

2Department of Medicine, Instituto do Cancer do Ceara, Brazil

3Department of Medicine, Universidade Federal do Ceara, Brazil

4Department of Medicine, Centro Universitario para o Desenvolvimento do Alto Vale do Itajai, Brazil



Know the tumor stage of breast cancer and identify the immunohistochemical markers are important in the evaluation of predictive and prognostic factors, in the differential diagnosis of breast lesions and in the determination of the possible origin of metastatic neoplasms, besides helping to define the type of treatment.


Cross-sectional and quantitative study of patients diagnosed with breast cancer, submitted to treatment at the Ceara Cancer Institute (ICC) mastology service from 2008 to 2012. Describe the main clinical and epidemiological characteristics of breast cancer treated at Haroldo Juacaba Hospital - Ceara Cancer Institute (ICC): Identify types of breast cancer; to evaluate the initial staging, correlating axillary status, local and systemic treatment; to analyze the immunohistochemical profile through receptors standardized by the pathology department of the Hospital, correlating them with the current molecular classification of breast cancer.


A total of 453 medical records were included. 41.5% of the patients had tumor in the T2 stage, 15.9% in the T1 stage, 12.6% in the T4 stage, 11.9% and in the T3 stage, 11.3% had tumor in situ. As for lymph nodes, 61.6% of them were in N0, 24.5% in N1, 13.0% in N2 and 0.9% in N3. 57% of the patients were sentinel node biopsy, 31% of the positive frozen. No significant amount of distant metastasis was identified. Regarding tumor type, 89.38% are ductal, 5.09% are lobular, 0.88% are tubular, 0.66% are mucinous and 7.30% are other types or mixed. With hormone receptor analysis, we obtained 38.3% of luminal type A tumors, 32.8% luminal type B, 21.8% Triple Negative type and 7.2% CERB B2 type.


Patients were predominantly classified at the IIA clinical stage. The invasive ductal carcinoma subtype is the most prevalent and there is predominance of the luminal molecular pattern, with discrete superiority of luminal pattern A over luminal B.